This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Peuskens, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peuskens, J.

The British Journal of Psychiatry 166: 712-726 (1995)
© 1995 The Royal College of Psychiatrists

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

J Peuskens
Universitair Centrum St Jozef, Kortenberg, Belgium.

BACKGROUND. This study was performed in order to evaluate the short- term efficacy and safety of fixed risperidone doses compared to haloperidol. METHOD. In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks. Efficacy was assessed by the Positive and Negative Syndrome Scale for schizophrenia (PANSS) and clinical global impression (CGI), and safety primarily by the Extrapyramidal Symptom Rating Scale (ESRS). RESULTS. One thousand three hundred and sixty-two patients were evaluated. The optimum risperidone doses were 4 mg and 8 mg, with response rates of 63.4% (56.8%; 69.7%) and 65.8% (59.2%; 71.9%) respectively. Response rate in haloperidol-treated patients was 58.7% (52.0%; 65.3%); the 95% confidence intervals (CI) of the differences between risperidone 4 mg or 8 mg and haloperidol were (- 4.3%; 13.7%) and (- 1.9%; 16.0%) respectively. There were no significant differences in CGI scores at endpoint between risperidone 4 mg, 8 mg, 12 mg and 16 mg and haloperidol (3.0, 3.0, 3.2, 3.1 and 3.1 respectively); the 95% CI of the differences between risperidone 4 mg or 8 mg and haloperidol were ( - 0.4; 0.1) and ( - 0.3; 0.2) respectively. Mean shifts to the maximum total ESRS scores versus baseline (mean (confidence interval)) were significantly greater in haloperidol-treated patients (5.1 (4.0; 6.2)) than in the risperidone 1, 4, 8 and 12 mg groups (1.1 (0.3; 1.9); 1.8 (0.9; 2.7); 2.7 (1.8; 3.6) and 3.2 (2.3; 4.1) respectively (P < 0.05)). CONCLUSION. Risperidone is an effective antipsychotic for the treatment of chronic schizophrenia; doses of 4 and 8 mg seem to be optimal and have a lower incidence of side-effects than haloperidol.


This article has been cited by other articles:


Home page
 Schizophr BullHome page
M. Obermeier, A. Mayr, R. Schennach-Wolff, F. Seemuller, H.-J. Moller, and M. Riedel
Should the PANSS Be Rescaled?
Schizophr Bull, November 4, 2009; (2009) sbp124v1.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov
Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features
Schizophr Bull, July 1, 2009; 35(4): 775 - 788.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
J. de Leon, N. B. Sandson, and K. L. Cozza
A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part II
Psychosomatics, July 1, 2008; 49(4): 347 - 361.
[Full Text] [PDF]

Home page
 PsychosomaticsHome page
J. de Leon, N. B. Sandson, and K. L. Cozza
A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part I
Psychosomatics, May 1, 2008; 49(3): 258 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
J. Rabinowitz and O. Davidov
The Association of Dropout and Outcome in Trials of Antipsychotic Medication and Its Implications for Dealing With Missing Data
Schizophr Bull, March 1, 2008; 34(2): 286 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
K. L. Claxton, J. J. Chen, and D. M. Swope
Drug-Induced Movement Disorders
Journal of Pharmacy Practice, December 1, 2007; 20(6): 415 - 429.
[Abstract] [PDF]

Home page
 Am J EpidemiolHome page
B. L. Lambert, F. E. Cunningham, D. R. Miller, G. W. Dalack, and K. Hur
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Am. J. Epidemiol., October 1, 2006; 164(7): 672 - 681.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics
Am J Psychiatry, February 1, 2006; 163(2): 185 - 194.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
N. Ezewuzie and D. Taylor
Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia
J Psychopharmacol, January 1, 2006; 20(1): 86 - 90.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
P. J. Weiden
Switching antipsychotics: an updated review with a focus on quetiapine
J Psychopharmacol, January 1, 2006; 20(1): 104 - 118.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
G. Kemmler, M. Hummer, C. Widschwendter, and W. W. Fleischhacker
Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis
Arch Gen Psychiatry, December 1, 2005; 62(12): 1305 - 1312.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
S. W. Woods, R. V. Gueorguieva, C. B. Baker, and R. W. Makuch
Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Arch Gen Psychiatry, September 1, 2005; 62(9): 961 - 970.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
D. G. Contopoulos-Ioannidis, S. M. Gilbody, T. A. Trikalinos, R. Churchill, K. Wahlbeck, J. P.A. Ioannidis, and The EU-PSI Project
Comparison of Large Versus Smaller Randomized Trials for Mental Health-Related Interventions
Am J Psychiatry, March 1, 2005; 162(3): 578 - 584.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
J. E. Hovens, P. J. T. Dries, C. T. M. Melman, R. J. C. Wapenaar, and A. J. M. Loonen
Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study
J Psychopharmacol, January 1, 2005; 19(1): 51 - 57.
[Abstract] [PDF]

Home page
 DTBHome page
Which atypical antipsychotic for schizophrenia?
DTB, August 1, 2004; 42(8): 57 - 60.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
T. Furukawa
Meta-analyses and megatrials: neither is the infallible, universal standard
Evid. Based Ment. Health, May 1, 2004; 7(2): 34 - 35.
[Full Text] [PDF]

Home page
 FocusHome page
M. D. Jibson, I. D. Glick, and R. Tandon
Schizophrenia and Other Psychotic Disorders
Focus, January 1, 2004; 2(1): 17 - 30.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman
Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder
Focus, January 1, 2004; 2(1): 59 - 67.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
G. G Liu, S. X Sun, D. B Christensen, and X. Luo
Cost Comparisons of Olanzapine and Risperidone in Treating Schizophrenia
Ann. Pharmacother., January 1, 2004; 38(1): 134 - 141.
[Abstract] [Full Text] [PDF]

Home page
 J Am Psychiatr Nurses AssocHome page
L. H. Beebe
Health Promotion in Persons with Schizophrenia: Atypical Medications
Journal of the American Psychiatric Nurses Association, August 1, 2003; 9(4): 115 - 122.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
C. Paton, R. Duffett, M. Harrington, P. Lelliott, C. Okocha, and T. Sensky
Patterns of Antipsychotic and Anticholinergic Prescribing for Hospital Inpatients
J Psychopharmacol, June 1, 2003; 17(2): 223 - 229.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. M. Davis, N. Chen, and I. D. Glick
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Arch Gen Psychiatry, June 1, 2003; 60(6): 553 - 564.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
A. WIECK and P. M. HADDAD
Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: Selective literature review
The British Journal of Psychiatry, March 1, 2003; 182(3): 199 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
Y. Vanina, A. Podolskaya, K. Sedky, H. Shahab, A. Siddiqui, F. Munshi, and S. Lippmann
Body Weight Changes Associated With Psychopharmacology
Psychiatr Serv, July 1, 2002; 53(7): 842 - 847.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
R. W. Buchanan, J. Kreyenbuhl, J. M. Zito, and A. Lehman
Relationship of the Use of Adjunctive Pharmacological Agents to Symptoms and Level of Function in Schizophrenia
Am J Psychiatry, June 1, 2002; 159(6): 1035 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
G. J. E. Schmitt, E. M. Meisenzahl, S. Dresel, K. Tatsch, B. Rossmuller, T. Frodl, U. W. Preuss, K. Hahn, and H.-j. Moller
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine
J Psychopharmacol, May 1, 2002; 16(3): 200 - 206.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman
Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder
Am J Psychiatry, February 1, 2002; 159(2): 255 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
J.-M. Azorin, R. Spiegel, G. Remington, J.-M. Vanelle, J.-J. Pere, M. Giguere, and I. Bourdeix
A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Severe Chronic Schizophrenia
Am J Psychiatry, August 1, 2001; 158(8): 1305 - 1313.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Bull.Home page
P. Bebbington
Choosing antipsychotic drugs in schizophrenia: A personal view
Psychiatr. Bull., August 1, 2001; 25(8): 284 - 286.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
P. M. Haddad, J. S. E. Hellewell, and A. Wieck
Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports
J Psychopharmacol, July 1, 2001; 15(4): 293 - 295.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
S. Kapur and P. Seeman
Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Am J Psychiatry, March 1, 2001; 158(3): 360 - 369.
[Abstract] [Full Text]

Home page
 Br. J. PsychiatryHome page
P. F. LIDDLE, C. J. LANE, and E. T.C. NGAN
Immediate effects of risperidone on cortico--striato--thalamic loops and the hippocampus
The British Journal of Psychiatry, November 1, 2000; 177(5): 402 - 407.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
S. G. Siris
Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents
Am J Psychiatry, September 1, 2000; 157(9): 1379 - 1389.
[Abstract] [Full Text]

Home page
 Am. J. PsychiatryHome page
D. V. Jeste, A. Okamoto, J. Napolitano, J. M. Kane, and R. A. Martinez
Low Incidence of Persistent Tardive Dyskinesia in Elderly Patients With Dementia Treated With Risperidone
Am J Psychiatry, July 1, 2000; 157(7): 1150 - 1155.
[Abstract] [Full Text]

Home page
 Psychiatr. Bull.Home page
S. Smith and M. Henderson
What you don't know won't hurt you: Information given to patients about the side-effects of antipsychotic drugs
Psychiatr. Bull., May 1, 2000; 24(5): 172 - 174.
[Abstract] [Full Text]

Home page
 NeurologyHome page
J. Windhaber, S. Urbanits, W. Grisold, M. F. Mazurek, and P. I. Rosebush
Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone
Neurology, April 11, 2000; 54(7): 1542 - 1546.
[Full Text] [PDF]

Home page
 NeurologyHome page
P. P. De Deyn, K. Rabheru, A. Rasmussen, J. P. Bocksberger, P. L. J. Dautzenberg, S. Eriksson, and B. A. Lawlor
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
Neurology, September 1, 1999; 53(5): 946 - 946.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
S. Nyberg, B. Eriksson, G. Oxenstierna, C. Halldin, and L. Farde
Suggested Minimal Effective Dose of Risperidone Based on PET-Measured D2 and 5-HT2A Receptor Occupancy in Schizophrenic Patients
Am J Psychiatry, June 1, 1999; 156(6): 869 - 875.
[Abstract] [Full Text]

Home page
 Am. J. PsychiatryHome page
P. Truffinet, C. A. Tamminga, L. F. Fabre, H. Y. Meltzer, M.-E. Rivière, and C. Papillon-Downey
Placebo-Controlled Study of the D4/5-HT2A Antagonist Fananserin in the Treatment of Schizophrenia
Am J Psychiatry, March 1, 1999; 156(3): 419 - 425.
[Abstract] [Full Text]

Home page
 NeurologyHome page
P. I. Rosebush and M. F. Mazurek
Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone
Neurology, March 1, 1999; 52(4): 782 - 782.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
G. REMINGTON, S. KAPUR, and R. ZIPURSKY
APA Practice Guideline for Schizophrenia: Risperidone Equivalents
Am J Psychiatry, September 1, 1998; 155(9): 1301a - 1302.
[Full Text]

Home page
 Research on Social Work PracticeHome page
K. J. Bentley
Psychopharmacological Treatment of Schizophrenia: What Social Workers Need to Know
Research on Social Work Practice, July 1, 1998; 8(4): 384 - 405.
[Abstract] [PDF]

Home page
 Stat Methods Med ResHome page
T. Johnson
Clinical trials in psychiatry: background and statistical perspective
Statistical Methods in Medical Research, June 1, 1998; 7(3): 209 - 234.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
G. Bondolfi, H. Dufour, M. Patris, J. P. May, U. Billeter, C. B. Eap, and P. Baumann
Risperidone Versus Clozapine in Treatment-Resistant Chronic Schizophrenia: A Randomized Double-Blind Study
Am J Psychiatry, April 1, 1998; 155(4): 499 - 504.
[Abstract] [Full Text]

Home page
 J Am Psychiatr Nurses AssocHome page
K. H. Littrell and S. H. Littrell
Treatment-refractory Schizophrenia: Update on Concepts and Interventions
Journal of the American Psychiatric Nurses Association, February 1, 1998; 4(1): S18 - S28.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
S. Nyberg and L. Farde
The relevance of serotonergic mechanisms in the treatment of schizophrenia has not been confirmed
J Psychopharmacol, January 1, 1997; 11(1): 13 - 14.
[PDF]

Home page
 J PsychopharmacolHome page
Fujian Song
Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials
J Psychopharmacol, January 1, 1997; 11(1): 65 - 71.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
G. Mercer, A. Finlayson, E. C. Johnstone, C. Murray, and D. G. C. Owens
A study of enhanced management in patients with treatment-resistant schizophrenia
J Psychopharmacol, January 1, 1997; 11(4): 349 - 356.
[Abstract] [PDF]

Home page
 DTBHome page
The drug treatment of patients with schizophrenia
DTB, November 1, 1995; 33(11): 81 - 86.
[Abstract] [Full Text] [PDF]